Immunotherapy for Glioblastoma: Playing Chess, Not Checkers CLINICAL CANCER RESEARCH Jackson, C. M., Lim, M. 2018; 24 (17): 4059–61


Patients with glioblastoma (GBM) exhibit a complex state of immune dysfunction involving multiple mechanisms of local, regional, and systemic immunosuppression and tolerance. These pathways are now being identified and their relative contributions explored. Delineating how these pathways are interrelated is paramount to effectively implementing immunotherapy for GBM. Clin Cancer Res; 24(17); 4059-61. ©2018 AACRSee related articles by Woroniecka et al., p. 4175 and Mohme et al., p. 4187.

View details for DOI 10.1158/1078-0432.CCR-18-0491

View details for Web of Science ID 000444040400001

View details for PubMedID 29691293